Your English writing platform
Discover LudwigSuggestions(1)
Exact(1)
In the phase 2 part of the study, 107 patients with ES received figitumumab at 30 mg/kg every 4 weeks for a median of 2 cycles (range, 1 16).
Similar(59)
For the final hypotheses testing, the p-values of the 2 parts of the study were calculated separately and then combined using Fisher's combination rule (p* = p1 × p2) and adjusted for type I error probability cα ≤ 0.0038.
Sample size for the Phase 1 part of the study was based on safety outcomes.
MT conceived of the HSP72 part of the study, and helped to draft the manuscript.
In the 2d part of the study, the population B was challenged with inhaled LPS.
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/13/111/prepub Part of the study was funded by the University Hospital of Würzburg.
We investigated the survival of children who received their diagnosis during the first (1980 1987) and last (1988 1996) part of the study period by Kaplan Meier plots.
EJGB performed analysis and wrote and approved the final manuscript The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/11/321/prepub Part of the study was funded by a kind donation of Vianex, SA, Greece.
Between February 2004 and February 2005, a further 1400 patients were randomised in the 2 × 2 factorial part of the study.
Capillary bleeding times were assessed (part 2 and part 3 of the study) before clopidogrel administration, 2, 4, and 12 h after clopidogrel administration, and following administration of dabigatran etexilate alone.
2) The part of the study about correlation of CD33 gene number with maximal life span in different mammalian species is interesting, but clearly very tenuous.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com